Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid

Abstract

Sorafenib has activity in ATC, but at a low frequency and similar to our previous experience with fosbretabulin. One patient with a response had previously progressed on fosbretabulin. Toxicities were both predictable and manageable.